Agilent Technologies (A) Fiscal Q2 2026 Earnings: What Analysts Expect and Key Factors to Watch
Key Takeaways
- Agilent Technologies is scheduled to report fiscal second-quarter 2026 results on May 27, 2026.
- Wall Street consensus calls for earnings per share of $1.41 and revenue of approximately $1.80 billion.
- The company has guided for Q2 revenue in the range of $1.79 billion to $1.82 billion.
- Investors will focus on core growth trends across life sciences, applied markets, and diagnostics segments.
- Historical stock reactions to recent earnings have been influenced by guidance updates and end-market demand signals.
- Broader industry conditions in analytical instruments and healthcare research remain key themes.
Earnings Context and Why It Matters
Agilent Technologies reports results on a fiscal year ending in October, making fiscal Q2 the three months ended April 30. The upcoming report follows solid first-quarter results and comes amid steady demand for the company’s analytical instruments and diagnostics solutions. Earnings provide critical updates on revenue growth, margins, and forward guidance, helping investors assess execution in key end markets such as pharmaceuticals, environmental testing, and clinical diagnostics. Strong or weak results can influence sentiment toward the broader life sciences tools sector.
Earnings Expectations
Analysts expect Agilent Technologies (A) to report earnings per share of $1.41 for fiscal Q2 2026, based on 14 estimates ranging from $1.39 to $1.42. Revenue consensus stands near $1.80 billion, with projections spanning $1.78 billion to $1.81 billion. The company’s own guidance points to revenue between $1.79 billion and $1.82 billion, implying reported growth of roughly 7% to 9% and core growth of 4% to 6%. Investors will also monitor segment performance, operating margins, and any updates to full-year outlook. In the prior-year Q2, Agilent delivered EPS of $1.31, providing a year-over-year comparison benchmark. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Heading into the report, investor sentiment reflects cautious optimism supported by stable demand in core markets and the company’s recent guidance. Historical post-earnings moves have varied depending on whether results and outlook met, exceeded, or fell short of expectations. Key risk factors include potential softness in certain end markets, currency fluctuations, and any shifts in capital spending by customers. Pre-earnings positioning often focuses on volatility around the release and subsequent analyst commentary. One thing that stands out from reviewing recent patterns is how guidance updates have driven the largest moves.
Using AI Tools to Refine My View
In my research process, I frequently rely on Tickeron’s AI-powered tools to cross-check assumptions and identify supporting signals. The AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. This approach has been useful for placing Agilent’s metrics in broader context without replacing fundamental analysis.
Forward Outlook and Key Factors to Monitor
Following the earnings release, attention will turn to management’s commentary on full-year fiscal 2026 guidance and any adjustments to segment outlooks. Investors should watch for updates on order trends, particularly in life sciences and applied markets, as well as progress in new product launches and geographic performance, especially in China and other Asia-Pacific regions.
Margin dynamics will remain a focus, including the impact of product mix, pricing, and operating expenses. Supply chain stability and any commentary on customer capital budgets could also influence perceptions of near-term growth sustainability.
Broader industry conditions, such as pharmaceutical research and development spending and environmental testing demand, will provide additional context. Upcoming catalysts may include conference presentations and potential updates on strategic initiatives. I’m watching this closely for any signals on sustained demand trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A's RSI Oscillator recovers from overbought zone
The 10-day RSI Indicator for A moved out of overbought territory on June 08, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 instances where the indicator moved out of the overbought zone. In of the 29 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on A as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for A turned negative on June 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where A declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for A entered a downward trend on May 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
A moved above its 50-day moving average on May 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for A crossed bullishly above the 50-day moving average on May 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where A advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .
A may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.015) is normal, around the industry mean (12.431). P/E Ratio (25.400) is within average values for comparable stocks, (145.825). Projected Growth (PEG Ratio) (1.242) is also within normal values, averaging (1.482). Dividend Yield (0.008) settles around the average of (0.008) among similar stocks. P/S Ratio (4.968) is also within normal values, averaging (7.245).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. A’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. A’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of measurement and monitoring instruments
Industry MedicalSpecialties
Advertisement